Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  LightPath Technologies, Inc.    LPTH   US5322578056

 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/25/2015 02/26/2015 02/27/2015 03/02/2015 03/03/2015 Date
1.04(c) 0.99(c) 1.0314(c) 0.9745(c) 0.99 Last
2 215 21 311 8 700 2 218 4 432 Volume
+1.96% -4.81% +4.18% -5.52% +1.59% Change
More quotes
Company
LightPath Technologies, Inc. designs, develops, manufactures and distributes optical and infrared components.Its products include molded glass aspheric lenses and assemblies, infrared lenses and thermal imaging assemblies, fused fiber collimators and gradient index GRADIUM lenses.The company also... 
More about the company
Chart LIGHTPATH TECHNOLOGIES, IN
Duration : Period :
LightPath Technologies, In Technical Analysis Chart | LPTH | US5322578056 | 4-Traders
Full-screen chart
Financials ($)
Sales 2015 12,8 M
EBIT 2015 -0,75 M
Net income 2015 -
Debt 2015 -
Yield 2015 -
Sales 2016 14,2 M
EBIT 2016 0,57 M
Net income 2016 -
Debt 2016 -
Yield 2016 -
PER 2015 -
PER 2016
Capi. / Sales 2015 1,16x
Capi. / Sales 2016 1,05x
Capitalization 14,8 M
More Financials
Latest news on LIGHTPATH TECHNOLOGIES, IN
02/27 LIGHTPATH TECHNOLOGIES : to Present at the 27th Annual ROTH Conference on March ..
02/11 LIGHTPATH TECHNOLOGIES : Posts Fiscal 2015 Second Quarter Financial Results
02/05 LIGHTPATH TECHNOLOGIES : Results of Operations and Financial Condition, Financia..
02/05 LIGHTPATH TECHNOLOGIES : Announces Fiscal 2015 Second Quarter Financial Results
02/04 LIGHTPATH TECHNOLOGIES : Change in Directors or Principal Officers, Financial St..
02/04 LIGHTPATH TECHNOLOGIES : Announces Board Changes
02/03 LIGHTPATH TECHNOLOGIES : Amendments to Articles of Inc. or Bylaws; Change in Fis..
02/02 LIGHTPATH TECHNOLOGIES : Announces Strategic Growth Initiatives
More news
Sector news Glasses, Spectacles & Contact lenses
12:29p SMITH & NEPHEW : Acquires Colombian Distributor
12:18p C R BARD : CMS Approves Pass-Through Payment for Lutonix DCB for Outpatient Use
10:13a Stryker's $2 billion buyback plan deflates Smith & Nephew bid hopes
Plus d'actualités du secteur Glasses, Spectacles & Contact lenses


Comments 
Advertisement
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF